At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TAK Takeda Pharmaceutical Co Ltd
Trading 03-03 11:49:11 EST
17.99
-0.45
-2.47%
High17.99Low17.51Vol1.53M
Open17.79D1 Closing18.44Amplitude2.60%
Mkt Cap56.82BTradable Cap54.98BTotal Shares3.16B
T/O27.27MT/O Rate0.05%Tradable Shares3.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Alan Walshe Appointed General Manager of Takeda Canada
Dow Jones  ·  03-02 20:59
Press Release: Alan Walshe Appointed General Manager of Takeda Canada
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
TIPRANKS  ·  03-02 18:30
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
Takeda’s Cuvitru Safety Study: What a New Japanese Registry Update Means for TAK Investors
TIPRANKS  ·  02-21
Takeda’s Cuvitru Safety Study: What a New Japanese Registry Update Means for TAK Investors
Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps
Benzinga_recent_news  ·  02-20
Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps
Takeda Reports 47% of Patients Met Primary Endpoint in Entyvio Trial
Dow Jones  ·  02-20
Takeda Reports 47% of Patients Met Primary Endpoint in Entyvio Trial
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
TIPRANKS  ·  02-20
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
Takeda’s New Stroke Trial Adds Long-Term Optionality to TAK’s Pipeline
TIPRANKS  ·  02-19
Takeda’s New Stroke Trial Adds Long-Term Optionality to TAK’s Pipeline
Takeda’s HyQvia Study Tracks Real-World Use in Multiple Myeloma, Offering Gradual Upside for TAK Investors
TIPRANKS  ·  02-19
Takeda’s HyQvia Study Tracks Real-World Use in Multiple Myeloma, Offering Gradual Upside for TAK Investors
Takeda Targets Better Hereditary Angioedema Diagnosis With New AHAE Study
TIPRANKS  ·  02-19
Takeda Targets Better Hereditary Angioedema Diagnosis With New AHAE Study
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
MT Newswires Live  ·  02-18
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy
TIPRANKS  ·  02-14
Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy
Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update
TIPRANKS  ·  02-14
Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update
Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial
TIPRANKS  ·  02-12
Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial
Takeda granted Priority Review for oveporexton by FDA
TIPRANKS  ·  02-10
Takeda granted Priority Review for oveporexton by FDA
Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery
Benzinga  ·  02-10
Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery
Takeda Pharmaceutical Invests $1.7 Billion in Iambic to Expand AI-Powered Drug Discovery
Deep News  ·  02-09
Takeda Pharmaceutical Invests $1.7 Billion in Iambic to Expand AI-Powered Drug Discovery
Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors
TIPRANKS  ·  02-07
Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors
Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies
TIPRANKS  ·  02-07
Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies
Takeda Advances TAK-279 in Ulcerative Colitis: What Investors Should Watch Next
TIPRANKS  ·  01-31
Takeda Advances TAK-279 in Ulcerative Colitis: What Investors Should Watch Next
Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control
Benzinga  ·  01-29
Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control
No data available

Introduction

Company Name.
Takeda Pharmaceutical Co Ltd
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Issue price:
--